Your browser doesn't support javascript.
loading
New-onset diabetes is a predictive risk factor for pancreatic lesions in high-risk individuals: An observational cohort study.
Baydogan, Seyda; Mohindroo, Chirayu; Hasanov, Merve; Montiel, Maria F; Quesada, Pompeyo; Cazacu, Irina M; Luzuriaga Chavez, Adrianna A; Mork, Maureen E; Dong, Wenli; Feng, Lei; You, Y Nancy; Arun, Banu; Vilar, Eduardo; Brown, Powel; Katz, Matthew H G; Chari, Suresh T; Maitra, Anirban; Tamm, Eric P; Kim, Michael P; Bhutani, Manoop S; McAllister, Florencia.
Affiliation
  • Baydogan S; Departments of Clinical Cancer Prevention the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mohindroo C; Departments of Clinical Cancer Prevention the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hasanov M; Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD, USA.
  • Montiel MF; Departments of Clinical Cancer Prevention the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Quesada P; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cazacu IM; Departments of Clinical Cancer Prevention the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Luzuriaga Chavez AA; Departments of Clinical Cancer Prevention the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mork ME; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Dong W; Department of Gastroenterology, Hepatology, and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng L; Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • You YN; Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Arun B; Departments of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vilar E; Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Brown P; Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Katz MHG; Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chari ST; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Maitra A; Departments of Clinical Cancer Prevention the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tamm EP; Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kim MP; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bhutani MS; Departments of Clinical Cancer Prevention the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • McAllister F; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Endosc Ultrasound ; 13(2): 83-88, 2024.
Article in En | MEDLINE | ID: mdl-38947744
ABSTRACT
Background and

Objectives:

Pancreatic cancer (PC) is the third cause of cancer-related deaths. Early detection and interception of premalignant pancreatic lesions represent a promising strategy to improve outcomes. We evaluated risk factors of focal pancreatic lesions (FPLs) in asymptomatic individuals at hereditary high risk for PC.

Methods:

This is an observational single-institution cohort study conducted over a period of 5 years. Surveillance was performed through imaging studies (EUS or magnetic resonance imaging/magnetic resonance cholangiopancreatography) and serum biomarkers. We collected demographic characteristics and used univariate and multivariate logistic regression models to evaluate associations between potential risk factors and odd ratios (ORs) for FPL development.

Results:

A total of 205 patients completed baseline screening. Patients were followed up to 53 months. We detected FPL in 37 patients (18%) at baseline; 2 patients had lesions progression during follow-up period, 1 of them to PC. Furthermore, 13 patients developed new FPLs during the follow-up period. Univariate and multivariate analyses revealed that new-onset diabetes (NOD) is strongly associated with the presence of FPL (OR, 10.94 [95% confidence interval, 3.01-51.79; P < 0.001]; OR, 9.98 [95% confidence interval, 2.15-46.33; P = 0.003]). Follow-up data analysis revealed that NOD is also predictive of lesions progression or development of new lesions during screening (26.7% vs. 2.6%; P = 0.005).

Conclusions:

In a PC high-risk cohort, NOD is significantly associated with presence of FPL at baseline and predictive of lesions progression or new lesions during surveillance.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Endosc Ultrasound Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Endosc Ultrasound Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: China